79317-30-9

Basic information

• Product Name: methyl (4-formyl-2-methoxyphenoxy)acetate
• Synonyms: methyl 2-(4-formyl-2-methoxyphenoxy)acetate;methyl 2-(4-formyl-2-methoxy-phenoxy)acetate;methyl 2-(4-methanoyl-2-methoxy-phenoxy)ethanoate;ST5438535;ZINC00453601;methyl (4-formyl-2-methoxyphenoxy)acetate;(4-FORMYL-2-METHOXY-PHENOXY)-ACETIC ACID METHYL ESTER;ART-CHEM-BB B029256
• CAS NO: 79317-30-9
• Molecular Formula: C₁₁H₁₂O₅
• Molecular Weight: 224.22
• Mol File: 79317-30-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 345.1°C at 760 mmHg
• Flash Point: 186.9°C
• Appearance: /
• Density: 1.208g/cm³
• Vapor Pressure: 6.28E-05mmHg at 25°C
• Refractive Index: 1.53
• CAS DataBase Reference: methyl (4-formyl-2-methoxyphenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (4-formyl-2-methoxyphenoxy)acetate(79317-30-9)
• EPA Substance Registry System: methyl (4-formyl-2-methoxyphenoxy)acetate(79317-30-9)

Safety Data

• Hazardous Substances Data: 79317-30-9(Hazardous Substances Data)

Usage

General Description

Methyl (4-formyl-2-methoxyphenoxy)acetate is a chemical compound with the molecular formula C10H12O4. It is a methyl ester of (4-formyl-2-methoxyphenoxy)acetic acid, and it is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. methyl (4-formyl-2-methoxyphenoxy)acetate is a colorless to pale yellow liquid with a fruity, floral odor. It is soluble in organic solvents and has a low volatility. Methyl (4-formyl-2-methoxyphenoxy)acetate is mainly used in the production of active pharmaceutical ingredients and as a chemical building block for the synthesis of various organic compounds. It also has applications in the fragrance and flavor industry.

InChI:InChI=1/C11H12O5/c1-14-10-5-8(6-12)3-4-9(10)16-7-11(13)15-2/h3-6H,7H2,1-2H3

Upstream product

• 121-33-5 vanillin 
• 105-39-5 chloroacetic acid ethyl ester 
• 96-32-2 bromoacetic acid methyl ester 
• 96-34-4 methyl chloroacetate 
• 67-56-1 methanol 
• 1660-19-1 (4-formyl-2-methoxyphenoxy)acetic acid 
• 17759-76-1 ethyl 1-bromoformate 

Downstream Products

• 81836-89-7 2-methoxy-4-(3-methyl-5-oxo-1-phenyl-4-pyrazolylidenemethyl)phenoxyaceticacid ethyl ester 
• 182345-41-1 methyl 2-(4-(1,3-dioxolan-2-yl)-2-methoxyphenoxy)acetate 
• 1123756-81-9 (E,Z)-methyl 2-{4-[(2,4-dioxodihydrofuran-3(2H)-ylidene)methyl]-2-methoxyphenoxy}acetate 
• 761409-39-6 (4-Hydroxymethyl-2-methoxy-phenoxy)-acetic acid methyl ester 
• 163136-19-4 cannabisin F 

Relevant articles and documents

Recognition and Sensing of Guanidine-containing Biomolecules in Aqueous Medium

A dicarboxylate-based fluorescent receptor has been synthesized for the recognition of the guanidinium ion and guanidine-containing biomolecules in aqueous medium to address the issue of biomolecular interaction. The acyclic receptor binds to guests in a

Development of curcumin-based amyloid β aggregation inhibitors for Alzheimer's disease using the SAR matrix approach

Amyloid β (Aβ) aggregation inhibitor activity cliff involving a curcumin structure was predicted using the SAR Matrix method on the basis of 697 known Aβ inhibitors from ChEMBL (data set 2487). Among the compounds predicted, compound B was found to posses

Targeting receptor tyrosine kinase VEGFR-2 in hepatocellular cancer: Rational design, synthesis and biological evaluation of 1,2-disubstituted benzimidazoles

In this study, a novel series of 1,2-disubstituted benzo[d]imidazoles was rationally designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. Our design strategy is twofold; it aimed first at studying the effect of replacing the 5-methylfuryl moiety of the well-known antiangiogenic 2-furylbenzimidazoles with an isopropyl moiety on the VEGFR-2 inhibitory activity and the cytotoxic activity. Our second objective was to further optimize the structures of the benzimidazole derivatives through elongation of the side chains at their one-position for the design of more potent type II-like VEGFR-2 inhibitors. The designed 1,2-disubstituted benzimidazoles demonstrated potent cytotoxic activity against the HepG2 cell line, reaching IC50 = 1.98 μM in comparison to sorafenib (IC50 = 10.99 μM). In addition, the synthesized compounds revealed promising VEGFR-2 inhibitory activity in the HepG2 cell line, e.g., compounds 17a and 6 showed 82% and 80% inhibition, respectively, in comparison to sorafenib (% inhibition = 92%). Studying the effect of 17a on the HepG2 cell cycle demonstrated that 17a arrested the cell cycle at the G2/M phase and induced a dose-dependent apoptotic effect. Molecular docking studies of the synthesized 1,2-disubstituted benzimidazoles in the VEGFR-2 active site displayed their ability to accomplish the essential hydrogen bonding and hydrophobic interactions for optimum inhibitory activity.